Stem Cell Therapy International, Inc. (OTCBB: SCII) is proud to announce the execution of the Reorganization and Stock Purchase Agreement ("the Agreement") with Histostem Co., Ltd., a Korean company ("Histostem" and together with SCII, "the parties"). This results in one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity. Following the execution of the Agreement, AmStem International, Inc. ("AmStem") -- a wholly owned subsidiary of SCII -- will be managing the U.S. operations of Histostem.
David Stark, SCII President and CEO, has been working closely with Histostem's management to finalize the Agreement, and is now working to secure the supply channels that will strengthen the Company's cash flow. Immediate plans include launching a worldwide distribution of existing cosmetic products, including a unique stem cell facial cream. Additional revenue is expected from the development of proprietary technologies from Dr. Han Hoon, CEO of Histostem, who will be working together with AmStem to bring new products to the U.S. and E.U. markets as soon as possible.
Highlights of Histostem include:
-- Histostem has the one of the world's largest, fully accredited repository of cord blood units (CBUs) and stem cells in the world (more than twice as large as its nearest competitor); with over 80,000 CBUs ready for immediate transfer. (See more details on Histostem below.) -- Histostem is the only company in the world to have full KFDA approval to use its cord blood derived stem cells directly for the treatment of disease. Clinical trials have been in progress for over 2 years to treat diseases such as Buerger's, Alzheimer's and Parkinson's, as well as Diabetes Mellitus, Hair Loss and ALS. -- Histostem has successfully developed a popular stem cell facial cream for the rejuvenation of skin, which is ready for worldwide distribution.
"The response to our stem cell cream has been extremely positive," states Mr. Stark, "and because we have a proven market presence in Asia, proprietary supply chain, GMP-approved manufacturing facility, and some very promising study results, we are ready to partner with a major distributor right now."
Clinical trials will be upgraded immediately, leveraged by the vast experience of Mr. Stark and his colleagues, who have a combined 30 years' experience in international regulatory affairs. New and improved trials will be run in South Korea by AmStem; under strict guidance of the KFDA, and in adherence to ICH guidelines, as part of a 2-year plan to validate earlier, successful outcomes in Histostem trials.